Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05670951

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Conditions: Intestinal Malabsorption

Sex: All

Ages: 1 Day – 5 Days

Phase: PHASE3

Enrollment: 360

Sponsor: Elgan Pharma Ltd.

Summary

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Eligibility Criteria

Inclusion Criteria:Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasoundBirth weight ≥ 500gSingleton or twin birthExclusion Criteria:-

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05670951). StuddyBuddy aggregates publicly available trial information.